Investigational Med for Tourette Syndrome Promising

PHILADELPHIA — The investigational agent ecopipam reduces tic severity in children and adolescents with Tourette syndrome (TS) without exacerbating common psychiatric comorbidities, results of a new analysis suggest. As previously reported, the first-in-class dopamine-1 (D1) receptor antagonist reduced the primary endpoint of tic severity scores by 30% compared with placebo among 149 patients in the ...

https://teach.coursemateai.com/home/course/get-it-done/163 
Get In Touch

Cape Breton, NS

+012 345 67890

Chris@websurfer.ca

Follow Us
Flickr Photos

Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved